AVIR today
$4.17-$0.05 (-1.18%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $3.62
Key levels
Resistance$4.93
Resistance$4.50
Support$3.94
Support$3.62
Latest news & SEC filings
EarningsAtea Pharmaceuticals posts smaller Q3 loss than expected
EarningsAtea Pharmaceuticals Posts Q3 2026 Financial Results
EarningsAtea Pharmaceuticals holds Q3 2026 earnings call
SEC FilingAtea Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)
All AVIR news →About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops oral antiviral treatments for serious viral infections. Its lead program combines bemnifosbuvir and ruzasvir to treat hepatitis C, and it is also developing AT-587 for persistent hepatitis E infection in people with weakened immune systems. The company's product candidates are based on its proprietary nucleoside and nucleotide platform.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
Atea Pharmaceuticals, Inc. (AVIR)
What Is the Price Target for AVIR?
SEPT Low Target
$7.00
SEPT Mid Target
$7.00
SEPT High Target
$7.00
Analyst Consensus
$7.00
Is AVIR a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AVIR.
Start Free Trial →Is AVIR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.81
12
Moat Score
NONE
2/9
Piotroski Score
2.0
Altman Z-Score
What Is Smart Money Doing with AVIR?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Murphy Polly A. | director | Buy | 6,100 | $25K | May 18, 2026 |
| Murphy Polly A. | director | Buy | 6,100 | $25K | May 18, 2025 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AVIR Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
3%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for AVIR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AVIR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:53:52 | $4.14 | 1,000 | $$4K | SELL |
| 21:00:23 | $4.22 | 1,600 | $$7K | SELL |
| 19:57:55 | $4.26 | 1,000 | $$4K | MIDPOINT |
| 19:42:55 | $4.24 | 1,089 | $$5K | BUY |
| 19:28:09 | $4.24 | 4,001 | $$17K | MIDPOINT |
5 dark pool trades shown · $$37K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Atea Pharmaceuticals, Inc. (AVIR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AVIR — frequently asked questions
What is AVIR stock price today?
Atea Pharmaceuticals, Inc. (AVIR) is at $4.17, down 1.18% (-$0.05) at the Nov 12, 2026 close.
Why is AVIR stock moving today?
Latest AVIR news — Nov 9, 2026: Atea Pharmaceuticals posts smaller Q3 loss than expected · Nov 9, 2026: Atea Pharmaceuticals Posts Q3 2026 Financial Results
What is the AVIR price target?
The average analyst price target for AVIR is $7.00, ranging from $7 to $7, based on 1 analysts. Latest: Morgan Stanley maintains on Aug 13, 2026.
What do analysts rate AVIR?
Analyst ratings for AVIR: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did AVIR beat earnings?
AVIR last reported on Aug 12, 2026: EPS -$0.41 vs -$0.56 expected — a beat of 26.1%.
Does AVIR pay a dividend?
AVIR does not currently pay a dividend.
What are AVIR support and resistance levels?
Support: $3.94, $3.62, $3.34. Resistance: $4.50, $4.93, $5.23.
What are insiders doing with AVIR?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on AVIR?
Nov 9, 2026: Atea Pharmaceuticals posts smaller Q3 loss than expected · Nov 9, 2026: Atea Pharmaceuticals Posts Q3 2026 Financial Results · Nov 9, 2026: Atea Pharmaceuticals holds Q3 2026 earnings call